pharmaceuticals

When looking to make an investment, some investors might look to get into what’s “in” or what’s “hot.” This is why gold has recently been on an amazing bull run (which is now effectively over), and why housing was hot before it. Much of this can be seen as a...

When it comes to buying stocks, everyone wants to pick a winner. But when investors are faced with two very similar stocks for competing companies in the same market it can be challenging to choose the best one. The drug store market has seen several companies perform well on Wall Street but...

Many investors are leery of OTC, or over-the-counter, stocks – and there are plenty of good reasons for that caution. OTC stocks often involve companies too small to be listed and traded on the coventional and better-known stock exchanges. They can include so-called “penny stocks” – defined by the...

The plot deepens regarding the biotech company Amarin (NASDAQ: AMRN) and its controversial cholesterol-controlling drug, Vascepa. As previously reported on Benzinga, Amarin was waiting to hear the results of a Food and Drug Administration ruling. The company had appealed the FDA's October...

A bribery scandal in China is forcing GlaxoSmithKline (NYSE: GSK) to review all of its business practices, The Financial Times reported. Four of GlaxoSmithKline's top Chinese executives have been arrested and dozens more questioned in an ongoing corruption investigation. Chinese police allege...

Is Amarin's (NASDAQ: AMRN) Vascepa the victim of its own ineptitude, or the target of an effort by Big Pharma to keep it off the market? Those questions and others have been lobbed around lately by a variety of industry observers and investors, regarding Amarin's sole product, Vascepa – a...

If you have a school-age child, you probably know how serious the issue of food allergies -- and an allergic reaction -- can be. The Centers for Disease Control and Prevention says about 88 percent of the nation's schools have one or more students with a serious food allergy – a health...

Another indication that while the overall economy may be recovering, the American workforce is still finding it difficult to stay fully employed. Data released Wednesday by the outplacement consulting firm Challenger, Gray & Christmas reports the nation's employers announced plans to cut 45...

Despite the technical difficulties and the government shutdown, the Affordable Care Act has launched in most states with others soon to follow. Primary beneficiaries of the Affordable Care Act are the previously uninsured, who will now enjoy more affordable access to healthcare. The...